期刊文献+

国产坎地沙坦酯片治疗轻中度原发性高血压的疗效和安全性 被引量:19

Clinical Efficacy and Safety of Candesartan Cilexetil in Patients with Mild-to-Moderate Essential Hypertension
在线阅读 下载PDF
导出
摘要 目的 评价坎地沙坦酯片治疗轻中度原发性高血压的疗效和安全性。方法 随机、双盲、双模拟、阳性药物 (氯沙坦 )平行对照。 6 1例轻、中度原发性高血压服用坎地沙坦酯片或氯沙坦片各 1片 ,1次 /d ,必要时增加剂量 1次。总疗程 8周。结果 氯沙坦组治疗前的血压为 (14 6 .2±11.6 ) / (10 0 3± 3.3)mmHg,治疗后的血压为 (130 3± 9.8) / (85 .7± 8 0 )mmHg,血压下降幅度为(16 0± 11.8) / (14 .6± 6 .8)mmHg;坎地沙坦酯组治疗前的血压为 (14 3.4± 11.2 ) / (10 0 6± 4 .1)mmHg,治疗后的血压为 (130 4± 11.2 ) / (86 .3± 8 0 )mmHg,血压下降幅度为 (13 0± 8.7) / (14 .3±6 .5 )mmHg。两组治疗后血压降低幅度均有统计学意义 ,主要降幅均在前 2周。组间无差异。治疗前后心率无明显变化。坎地沙坦酯和氯沙坦降压显效率分别为 6 0 7%和 6 0 0 % ,总有效率分别为82 .1%和 76 .7% ,组间无差别。不良事件坎地沙坦酯和氯沙坦组为头晕各 2例和 1例 ,血生化等实验室指标无异常改变。结论 国产坎地沙坦酯片治疗轻中度原发性高血压不良反应发生率很低 ,本文无 1例出现咳嗽 ,耐受性良好 ,适用于长期治疗。 Objective To evaluate the efficacy and safety of domest ic produced candesartan cilexetil in patients with mild-to-moderate essential hypertension. Methods Sixty one patients were randomLy assigned to receive candesartan cilexetil (8 mg/d) or losartan (50 mg/d) . The dosages wer e titrated to double the doses when DBP was sustained≥90 \{mm Hg\} or the magni tude of reduction was less than 10 \{mm Hg\}. Results Systolic bloo d pressure (SBP)/diastolic blood pressure (DBP) decreased significantly from (14 6.2±11.6)/(1003±3.3)\{mm Hg\} to (1303±9.8)/(85.7±80)\{mm Hg\} in losartan group and from (143.4±11.2)/(1006±4.1)\{mm Hg\} to (1304 ±11.2)/(86.3±80)\{mm Hg\} in candesartan group. The responsive rate was 82.1% in candesartan group, and 76.7% in losartan group. No change in heart ra te was found. Adverse reactions were slight. Conclusion Domestic produced candesartan cilexetil was proved to be a stable and efficacious antihyp ertensive medication with little adverse reactions. It appears as effective and safe as losartan and appears to be suitable for long term treatment of essentia l hypertension.
出处 《高血压杂志》 CSCD 2004年第5期404-407,共4页 Chinese Journal of Hypertension
关键词 国产坎地沙坦酯片 治疗 原发性高血压 安全性 疗效观察 Candesartan Losartan Hypertension
  • 相关文献

参考文献9

  • 1Gradman AH. AT-1-receptor blockers: differences that matter[J].J Hum Hypertens,2002,16:S9-S16.
  • 2Easthope SE,Jarvis B.Candesartan cilexetil: an update of its use in essential hypertension[J].Drugs,2002,62:1253-1287.
  • 3Zanchetti A,Omboni S. Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group[J].Am J Hypertens,2001,14:129-134.
  • 4Kloner RA,Weinberger M,Pool JL,et al. Comparative effects of candesartan cilexetil and amLodipine in patients with mild systemic hypertension. Comparison of candesartan and amLodipine for safety, Tolerability and efficacy (CASTLE) study investigators[J].Am J Cardiol,2001, 15,87:727-731.
  • 5Neldam S, Forsen B. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide[J].Drugs Aging,2001,18:225-232.
  • 6Bakris G,Gradman A,Reif M,et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study[J].J Clin Hypertens,2001,3:16-21.
  • 7Weir MR,Weber MA,Neutel JM,et al. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION study investigators[J].Am J Hypertens,2001,14:567-572.
  • 8Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study[J].BMJ, 2000,321:1440-4.
  • 9Lithell H,Hansson L,Skoog I,et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial[J].J Hypertens,2003,21:875-886.

同被引文献142

引证文献19

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部